Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 841 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperlipidaemia Clear all
Enrolling by invitation Not applicable Interventional

Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative

NCT06831162
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Hyperlipidemia, Health-related Social Problems
Interventions
Multi-level HRSN initiative
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

NCT01516879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 22, 2026, 5:50 PM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

NCT00090402
View directory record Official record
Conditions
Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
Interventions
Fish Oil, Lipoic Acid, Fish Oil Placebo, Lipoic Acid Placebo
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Aronia on Inflammation and the Gut Microbiome

NCT04128839
View directory record Official record
Conditions
Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions
Aronia berry juice, Sham comparator
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

NCT05238519
View directory record Official record
Conditions
Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Interventions
Motivational interview (MI)
Behavioral
Lead sponsor
Essentia Health
Other
Eligibility
2 Years to 75 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Active, not recruiting Phase 3 Interventional

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

NCT02262832
View directory record Official record
Conditions
Lipodystrophy, Diabetes, Hyperlipidemia
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 98 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Results available

Tailored Communication to Reduce Cardiovascular Risk

NCT01286311
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Artery Disease, Dyslipidemia, Hypertension
Interventions
Direct-to-patient tailored cardiovascular risk message system
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

NCT00385931
View directory record Official record
Conditions
Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions
Valsartan and simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

NCT00685737
View directory record Official record
Conditions
Hyperlipidemia
Interventions
1-MNA, Placebo
Drug
Lead sponsor
Pharmena North America
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2008 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

NCT04964544
View directory record Official record
Conditions
High Cholesterol
Interventions
5 mg rosuvastatin calcium with a Web App (combination product)
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

NCT01010841
View directory record Official record
Conditions
Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions
UltraMealPlus 360 (Medical food), Low-glycemic-load diet
Dietary Supplement · Other
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531
View directory record Official record
Conditions
Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions
Orlistat
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

NCT00753779
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

NCT00891293
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
32
States / cities
Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 22, 2026, 5:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities

NCT03206164
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Asynchronous, eLearning Intervention
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084
View directory record Official record
Conditions
Familial Chylomicronemia
Interventions
Plozasiran, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 4 Interventional

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, glyburide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Dietary Fiber on Blood Lipids in Men and Women

NCT02835872
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
dietary fiber
Other
Lead sponsor
Tate & Lyle
Industry
Eligibility
21 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 22, 2026, 5:50 PM EDT
Completed No phase listed Observational

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

NCT07023445
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37,688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 22, 2026, 5:50 PM EDT
Recruiting No phase listed Observational

Bempedoic Acid Pregnancy Surveillance Program

NCT05103254
View directory record Official record
Conditions
Pregnancy, Hyperlipidemias
Interventions
Bempedoic Acid, Bempedoic Acid / Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Timeline
2021 – 2032
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 22, 2026, 5:50 PM EDT